These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 10965399)

  • 1. Tolcapone: more than meets the eye?
    Deleu D; Hanssens Y
    Am J Health Syst Pharm; 2000 Aug; 57(16):1534. PubMed ID: 10965399
    [No Abstract]   [Full Text] [Related]  

  • 2. Update on "open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder".
    Moroz G; Magni G; Fava M
    J Clin Psychopharmacol; 2000 Apr; 20(2):285. PubMed ID: 10770481
    [No Abstract]   [Full Text] [Related]  

  • 3. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Henry C; Wilson JA
    Lancet; 1998 Jun; 351(9120):1965-6. PubMed ID: 9654299
    [No Abstract]   [Full Text] [Related]  

  • 4. Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations.
    Spahr L; Rubbia-Brandt L; Burkhard PR; Assal F; Hadengue A
    Dig Dis Sci; 2000 Sep; 45(9):1881-4. PubMed ID: 11052337
    [No Abstract]   [Full Text] [Related]  

  • 5. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects.
    Russ H; Müller T; Woitalla D; Rahbar A; Hahn J; Kuhn W
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):719-20. PubMed ID: 10619191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Harper J; Vieira B
    Lancet; 1998 Aug; 352(9127):578. PubMed ID: 9716090
    [No Abstract]   [Full Text] [Related]  

  • 7. Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a-catechol-o-methyl transferase inhibitor.
    Iwuagwu CU; Riley D; Bonoma RA
    Am J Med; 2000 Apr; 108(6):517-8. PubMed ID: 10866587
    [No Abstract]   [Full Text] [Related]  

  • 8. Tolcapone (Tasmar).
    Robertson S
    CMAJ; 1999 Apr; 160(7):1052, 1056. PubMed ID: 10207353
    [No Abstract]   [Full Text] [Related]  

  • 9. Lack of an effect of Madopar on the disposition of tolcapone and its 3-O-methylated metabolite in rats.
    Funaki T; Onodera H; Ushiyama N; Tsukamoto Y; Tagami C; Fukazawa H; Kuruma I
    J Pharm Pharmacol; 1995 Jun; 47(6):539-42. PubMed ID: 7674141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Serious tolpcapone-induced hepatitis 17 months after commencing treatment].
    Korri H; Awada A
    Rev Neurol (Paris); 2005 Nov; 161(11):1113-5. PubMed ID: 16288178
    [No Abstract]   [Full Text] [Related]  

  • 11. Tolcapone for Parkinson's disease.
    Med Lett Drugs Ther; 1998 Jun; 40(1028):60-1. PubMed ID: 9629124
    [No Abstract]   [Full Text] [Related]  

  • 12. Nitrocatechol derivatives as inhibitors of catechol-O-methyltransferase.
    Byrne JM; Tipton KF
    Biochem Soc Trans; 1996 Feb; 24(1):64S. PubMed ID: 8674740
    [No Abstract]   [Full Text] [Related]  

  • 13. Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase.
    Jorga K; Fotteler B; Heizmann P; Gasser R
    Br J Clin Pharmacol; 1999 Oct; 48(4):513-20. PubMed ID: 10583021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolcapone improves cognition and cortical information processing in normal human subjects.
    Apud JA; Mattay V; Chen J; Kolachana BS; Callicott JH; Rasetti R; Alce G; Iudicello JE; Akbar N; Egan MF; Goldberg TE; Weinberger DR
    Neuropsychopharmacology; 2007 May; 32(5):1011-20. PubMed ID: 17063156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolcapone, an inhibitor of catechol O-methyltransferase, counteracts memory deficits caused by bilateral cholinotoxin lesions of the basal nuclei of Meynert.
    Khromova I; Rauhala P; Zolotov N; Männistö PT
    Neuroreport; 1995 May; 6(8):1219-22. PubMed ID: 7662912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy.
    Borges N
    Drug Saf; 2003; 26(11):743-7. PubMed ID: 12908845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First COMT inhibitor approved for Parkinson's disease.
    Am J Health Syst Pharm; 1998 Mar; 55(6):524, 526. PubMed ID: 9544322
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
    Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
    J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
    Jorga KM; Sedek G; Fotteler B; Zürcher G; Nielsen T; Aitken JW
    Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro.
    Gerlach M; Ukai W; Ozawa H; Riederer P
    J Neural Transm (Vienna); 2002 May; 109(5-6):789-95. PubMed ID: 12111468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.